MR reports a consultancy from Bayer, Bristol Myers Squibb, Roche, Ipsen, Astra Zeneca, Boston Science, Lilly, and UniversalDX; lecture fees from Bayer, Bristol Myers Squibb, Gilead, Lilly, and ROCHE; travel support from Bayer, Bristol Myers Squibb, Lilly, and AstraZeneca; and research funding (paid to the institution) from Bayer and Ipsen. MR also received grant support from Instituto de Salud Carlos III (PI15/00145 and PI18/0358) and the Spanish Health Ministry (National Strategic Plan against Hepatitis C). MS-Z received speaker fees from Bayer and travel grants from Bayer, BTG, and Eisai-Merck Sharpe and Dohme; was supported by Ajuts per a la iniciació a la recerca 2019 from Societat Catalana de Digestologia (SCD); and received grant support from Instituto de Salud Carlos III (FI19/00222). Both authors are members of the European Reference Network (ERN) RARE-LIVER.